ASMI announces new Board
At its Annual General Meeting today, the Australian Self Medication Industry (ASMI) announced its new Board of Directors.
ASMI Chief Executive Officer, Deon Schoombie, congratulated and welcomed the ASMI Board Members.
"ASMI's new Board includes the recognised leaders of the non-prescription medicines industry. The Board's high level of expertise and industry knowledge will enable us to fully embrace tremendous opportunities and manage challenging issues in the years ahead.
"This is an exciting time for the industry as we drive regulatory reform to enhance consumer access to medicines and promote the integration of self care into national health policy.
"I'm looking forward to working with the new ASMI Board," he added.
Mark Sargent is the interim Chairman until the first Board meeting. Office-bearers will be elected at this meeting.
ASMI Board Members
Rob Barnes - Aspen PharmaCare
Shane Byrne - Perrigo
Lindsay Forrest - Lindsay Forrest Consultant
James Jones - Takeda
Phil Lynch - Johnson & Johnson Pacific
Alan Oppenheim - Ego Pharmaceuticals
Elizabeth Reynolds - GlaxoSmithKline Consumer Healthcare
Paul Rose - Pfizer
Mark Sargent - Bayer Australia